Business Context and Reporting Period
Company: Oragenics, Inc.
Filing Type: Form 8-K (Current Report)
Date: December 19, 2005
Context: The Company reported the closing of a private placement of common stock and warrants, changes to its Board of Directors, and the repayment of its bank loan.
Key Financial Metrics and Capital Structure
- Capital Raised: $1,175,000 from the private placement.
- Shares Issued: 2,937,500 shares of common stock at $0.40 per share.
- Warrants Issued to Investors: 2,937,500 warrants with an exercise price of $0.60 per share (2-year term).
- Warrants Issued to Advisor: 35,000 warrants at $0.40 and 95,000 warrants at $0.60 to Westrock Advisors.
- Debt Status: The Company voluntarily repaid all remaining principal and interest on its bank loan.
- Use of Proceeds: General corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, or margin data.
Material Changes and Corporate Actions
- Board Changes: Mento A. Soponis resigned from the Board of Directors. George Hawes, an investor who purchased 1,000,000 shares and 1,000,000 warrants, was appointed to fill the vacancy.
- Secondary Sales: Directors Jeffrey Hillman and Mento A. Soponis sold an aggregate of 1,200,000 shares for $1,200 to accredited investors participating in the private placement.
- Registration Rights: The Company is obligated to file a registration statement within 45 days covering the resale of shares purchased by private investors and shares issuable upon warrant exercise.
Outlook, Risks, and Unusual Items
- Warrant Call Provision: Warrants issued to investors are callable by the Company if the common stock trades at or above $1.20 per share for 30 consecutive days.
- Regulatory Compliance: The offering relied on the Section 4(2) exemption from registration under the Securities Act of 1933.
- Management Commentary: No specific forward-looking guidance or outlook was provided in this filing beyond the use of proceeds for general corporate purposes.
Investor Verification Checklist
- Verify the dilution impact of the 2,937,500 new shares and 3,067,500 total warrants issued.
- Confirm the current status of the registration statement required within 45 days of the November 20, 2005 agreement.
- Review the terms of the secondary sale where directors sold 1,200,000 shares for $1,200 (approx. $0.001 per share) to understand the valuation context.
- Monitor the stock price relative to the $1.20 call threshold for the warrants.